Home > News > Nanogen Announces Type II Diabetes Research Collaboration
May 15th, 2006
Nanogen Announces Type II Diabetes Research Collaboration
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, has announced a collaboration agreement with Oy Jurilab, Ltd., the Finnish genomics company. The collaboration is designed to identify and validate new prognostic markers for type II diabetes, one of the leading causes of death in the United States.
Source:
prnewswire
Bookmark:
| Related News Press |
Nanomedicine
Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017
Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017
Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017
Announcements
Solar-to-fuel system recycles CO2 to make ethanol and ethylene: Berkeley Lab advance is first demonstration of efficient, light-powered production of fuel via artificial photosynthesis September 19th, 2017
A new approach to ultrafast light pulses: Unusual fluorescent materials could be used for rapid light-based communications systems September 19th, 2017
New quantum phenomena in graphene superlattices September 18th, 2017
Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
University Technology Transfer & Patents
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||